Using nanotechnology to improve the success of arteriovenous fistulas for dialysis patients
Nanotechnology as a therapeutic approach in arteriovenous fistula maturation
This study is looking at how certain proteins and special tiny drug carriers can help improve the growth of arteriovenous fistulas (AVFs) for people on hemodialysis, aiming to make the process easier and more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10839381 on NIH RePORTER |
What this research studies
This research focuses on addressing the common issue of arteriovenous fistula (AVF) maturation failure in patients undergoing hemodialysis. The study aims to explore the role of specific proteins involved in AVF development and to test the effectiveness of drug-loaded nanoparticles that target the AVF site. By delivering medication directly to the affected area, the researchers hope to enhance the maturation process of the fistula while minimizing side effects. This innovative approach could lead to better outcomes for patients who rely on AVFs for dialysis.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with chronic kidney failure who require hemodialysis and are at risk of AVF maturation failure.
Not a fit: Patients who do not require hemodialysis or have no need for arteriovenous fistulas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the success rates of arteriovenous fistulas, leading to better dialysis access for patients.
How similar studies have performed: While targeted nanomedicine has shown promise in other areas, this specific application for AVF maturation is relatively novel and has not been extensively tested.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Shiu, Yan-Ting E. — University of Utah
- Study coordinator: Shiu, Yan-Ting E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.